Press Releases

Press Releases

Incyte Corporation today announced that the first patient has been treated in the REACH-1 pivotal Phase 2 trial evaluating ruxolitinib (Jakafi®) in combination with corticosteroids for the treatment of patients with steroid-refractory acute graft-versus-host disease (GVHD). “We are very pleased to have the first patient treated in the pivotal trial…

Press Releases

Research and Markets has announced the addition of the "Antifungal Drugs Market Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Allyamines), By Indication (Dermatophytosis, Aspergillosis, Candidiasis) And Segment Forecasts, 2014 - 2025" report to their offering. The global antifungal drugs market was valued at USD 10.7 billion in 2015 and is…

Press Releases

Mylan N.V. announced the U.S. launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg, a generic version of Janssen's Concerta® Tablets.  Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product,…

Press Releases

WHAT: Cornerstone Pharmaceuticals will present to investors and biopharmaceutical executives from around the world. The 9th Annual Conference Biotech Showcase™ is one of the largest annual healthcare conferences around the world and will take place in San Francisco concurrently to the J.P. Morgan 35th Annual Healthcare Conference. Members of Cornerstone's…

Press Releases

Escend Pharmaceuticals, Inc., a privately held company focused on the development of small molecule therapeutics for oncology orphan diseases, announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for its lead product candidate, ES-3000, for the treatment of acute myeloid leukemia (AML). The…

Press Releases

Achillion Pharmaceuticals, Inc. announced that it has received a $15 million milestone payment from Janssen Research & Development, LLC., part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), related to enrollment in the OMEGA-1 Phase 2b global, clinical trial of JNJ-4178, a 3DAA combination of odalasvir, simeprevir, and…

Press Releases

Seattle Genetics, Inc., a global biotechnology company, today announced that it has received notice from the U.S. Food and Drug Administration (FDA) that a clinical hold or partial clinical hold has been placed on several early stage trials of vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia (AML). The clinical holds…

Press Releases

Genervon Biopharmaceuticals LLC reported today that in advance of the upcoming JP Morgan Healthcare Conference in San Francisco in January it will publish the confidential list of genes associated with Amyotrophic Lateral Sclerosis (ALS) (89 genes) and Alzheimer’s disease (84 genes) that are modulated by GM6 to potentially bring homeostasis…

Press Releases

Gilead Sciences, Inc. today announced that its corporate presentation will be webcast from the 35th Annual J.P. Morgan Healthcare Conference in San Francisco. John F. Milligan, PhD, Gilead’s President and Chief Executive Officer, will provide an overview of the company at the conference on Monday, January 9 at 10:30 a.m.…

Press Releases

Within a week of Christmas day, a drug called nusinersen will be in the hands of doctors across the nation, who will use it, most urgently, to treat young children with a severe and potentially fatal illness called spinal muscular atrophy (SMA). The leading genetic cause of infant mortality, SMA…